Andrea John Ellis's most recent trade in BridgeBio Pharma Inc was a trade of 8,425 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 8,425 | 8,425 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 6,589 | 18,589 (0%) | 0% | 0 | Common Stock | |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2025 | 10,000 | 64,921 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 14 Apr 2025 | 10,000 | 12,000 (0%) | 0% | 35 | 350,000 | Common Stock |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.45 per share. | 14 Apr 2025 | 10,000 | 22,000 (0%) | 0% | 8.5 | 84,500 | Common Stock |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 30,000 | 74,921 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Sale of securities on an exchange or to another person at price $ 34.05 per share. | 01 Apr 2025 | 30,000 | 12,000 (0%) | 0% | 34.1 | 1,021,500 | Common Stock |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.45 per share. | 01 Apr 2025 | 30,000 | 42,000 (0%) | 0% | 8.5 | 253,500 | Common Stock |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 26,014 | 26,014 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 51,501 | 51,501 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 104,921 | 104,921 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Purchase of securities on an exchange or from another person at price $ 8.39 per share. | 15 Mar 2022 | 12,000 | 12,000 (0%) | 0% | 8.4 | 100,680 | Common Stock |
| BridgeBio Pharma Inc | Andrea John Ellis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2021 | 49,869 | 49,869 | - | - | Stock Option (right to buy) |